Guía de práctica clínica para tratamiento de fibrilación auricular
El tratamiento de la fibrilación auricular impone retos en cada caso. Nuestro propósito es brindar recomendaciones para el médico en atención primaria. Las fuentes de información principales en la elaboración de la guía fueron estudios primarios y agregativos.En general, el tratamiento de la fi brilación auricular requiere enfoque individualizado y es altamente recomendable aprovechar de manera pertinente las escalas clínicas disponibles para identificación de beneficios y riesgos según las alternativas terapéuticas.Para la toma de deciciones hay dos aspectos clave: 1) determinar justificación para profilaxis antitrombótica, 2) evaluar la estrategia más apropiada: control de frecuencia - control de ritmo. Las recomendaciones estan expuestas... Ver más
Guardado en:
0121-2133
2500-7181
21
2015-06-30
39
53
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Revista Cuarzo - 2015
| id |
361b8ccd5cd66f08ad9a281e70176c50 |
|---|---|
| record_format |
ojs |
| spelling |
Guía de práctica clínica para tratamiento de fibrilación auricular Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther. 2012;10(12):1471-80. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fi brillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-6. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-94. Benezet-Mazuecos J, Rubio JM, Cortés M, et al. Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices. Europace. 2015;17(3):364-9. Yoneyama K, Harada T, Ito H, et al. Subclinical atrial fi brillation preceding cardioembolic stroke in a patient with systolic heart failure. Int J Cardiol. 2014;176(3):1036-8. Wachter R, Stahrenberg R, Gröschel K. Subclinical atrial fi brillation: how hard should we look? Heart. 2013;99(3):151-3. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-9. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fi brillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fi brillation in developed and developing nations. Glob Heart. 2014;9(1):113-9. Chan N, Paikin J, Hirsh J, Lauw M, Eikelboom J, Ginsberg J. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thrombosis and Haemostasis. 2014;111(5):798807. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152(3):420-6. Chiang C-EE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632-9. Stępińska J, Czerwińska K, Witkowski A, et al. Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI). Cardiol J. 2013;20(2):125-33. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart. 2013;99(2):127-32. Claridge SB, Kanaganayagam GS, Kotecha T. Atrial fi brillation guidelines. Don’t forget HASBLED score. BMJ. 2011;342:d3205. Cope S, Clemens A, Hammès F, Noack H, Jansen JP. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fi brillation stroke prevention trials. Value Health. 2015;18(2):234-49. Basili S, Raparelli V, Proietti M, Napoleone L, Ferroni P, Franconi F. Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women. Curr Vasc Pharmacol. 2015. Dentali F, Botto GL, Gianni M, Ambrosino P, Di Minno MN. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature. Int J Cardiol. 2015;185:72-77. Senoo K, Lip GY. Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fi brillation. Semin Thromb Hemost. 2015;41(2):146-53. Albertsen I, Rasmussen L, Overvad T, Graungaard T, Larsen T, Lip G. Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin A Systematic Review and Metaanalysis. Stroke. 2013;44(5):1329-1336. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100(2):247-52. Dzeshka M, Lane D, Lip G. Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk-Score Acronyms (CHADS2, CHA2DS2-VASc, R2CHADS2, HAS-BLED, ATRIA, and More). Clinical Cardiology. 2014;37(10):634-644. info:eu-repo/semantics/article Text http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/publishedVersion http://purl.org/redcol/resource_type/ARTREV http://purl.org/coar/resource_type/c_dcae04bc http://purl.org/coar/resource_type/c_6501 Lafuente-Lafuente C, Valembois L, Bergmann J-FF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fi brillation. Cochrane Database Syst Rev. 2015;3:CD005049. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, fl ecainide, and propafenone, for the management of atrial fi brillation. Europace. 2011;13(3):329-45. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365(10):883-91. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361(12):1139-51. Wallentin L, Lopes RD, Hanna M, et al. Effi cacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166-76. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fi brillation. Europace. 2013;15(5):625-651. Rolf S, Kornej J, Dagres N, Hindricks G. What can rhythm control therapy contribute to prognosis in atrial fi brillation? Heart. 2015. Weipert KF, Erkapic D, Schmitt J. [Rate and rhythm control in atrial fibrillation: Pharmacological approaches]. Herz. 2015;40(1):16-24. Smit MD, Crijns HJ, Tijssen JG, et al. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fi brillation data of the RACE II (RAte Control Effi cacy in permanent atrial fi brillation II) study. J Am Coll Cardiol. 2011;58(9):942-9. Hrynkiewicz-Szymanska A, Dluzniewski M, Platek AE, et al. Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. J Thromb Thrombolysis. 2014. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fi brillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Annals of internal medicine. 2011;155(10):660-7, W204. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate and rhythm-control therapies in patients with atrial fi brillation: a systematic review. Ann Intern Med. 2014;160(11):760-73. https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/33 El tratamiento de la fibrilación auricular impone retos en cada caso. Nuestro propósito es brindar recomendaciones para el médico en atención primaria. Las fuentes de información principales en la elaboración de la guía fueron estudios primarios y agregativos.En general, el tratamiento de la fi brilación auricular requiere enfoque individualizado y es altamente recomendable aprovechar de manera pertinente las escalas clínicas disponibles para identificación de beneficios y riesgos según las alternativas terapéuticas.Para la toma de deciciones hay dos aspectos clave: 1) determinar justificación para profilaxis antitrombótica, 2) evaluar la estrategia más apropiada: control de frecuencia - control de ritmo. Las recomendaciones estan expuestas en tablas y algoritmos que requieren ser utilizadas según el contexto y características individuales en cada caso. Forero Supelano, Victor Hugo brilación auricular embolísmo anticoagulación sangrado guía práctica clínica atención primaria 21 1 Artículo de revista application/pdf Fundación Universitaria Juan N. Corpas Revista Cuarzo Publication Abraham JM, Connolly SJ. Atrial fi brillation in heart failure: stroke risk stratification and anticoagulation. Heart Fail Rev. 2014;19(3):305-13. Steinberg B, Kim S, Thomas L, et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2014;129(20):20052012. Bekwelem W, Misialek JR, Konety S, et al. Echocardiographic measures of cardiac structure and function are associated with risk of atrial fi brillation in blacks: the Atherosclerosis Risk in Communities (ARIC) study. PLoS ONE. 014;9(10):e110111. Luong C, Thompson DJ, Bennett M, et al. Right atrial volume is superior to left atrial volume for prediction of atrial fibrillation recurrence after direct current cardioversion. Can J Cardiol. 2015;31(1):29-35. Español https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Cuarzo - 2015 Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fi brillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377-87. Yoon YE, Oh I-YY, Kim S-AA, et al. Echocardiographic Predictors of Progression to Persistent or Permanent Atrial Fibrillation in Patients with Paroxysmal Atrial Fibrillation (E6P Study). J Am Soc Echocardiogr. 2015. Shi X-MM, Yuan H-TT, Guo H-YY, Guo J-PP, Shan Z-LL, Wang Y-TT. Electrophysiological characteristics of paroxysmal atrial fibrillation originating from superior vena cava: a clinical analysis of 30 cases. Int J Clin Exp Med. 2015;8(1):240-8. Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods for diagnosing atrial fi brillation using 12-lead ECG: A systematic review and meta-analysis. Int J Cardiol. 2015;184C:175-183. Penado S, Cano M, Acha O, Hernández J, Riancho J. Atrial fibrillation as a risk factor for stroke recurrence. The American Journal of Medicine. 2003;114(3):206210. anticoagulation Journal article embolism atrial fibrillation primary care guide clinical practice Atrial fIbrillation - practical clinical guideline Since the management of atrial fibrillation may be difficult in the individual patient, our purpose was to develop simple clinical recommendations to help the primary primary care physicians.SOURCES: Systematic review of the literature with evaluation of data-related evidence and framing of graded recommendations.SYNTHESIS: The management of atrial fibrillation requires individualised evaluation of the risks and benefits of therapeutic modalities, relying whenever possible on simple and validated tools. The two main points requiring a decision in clinical management are 1) whether or not to implement thromboembolic prevention therapy, and 2) whether preference should be given to a “rate control” or “rhythm control” strategy. To assist the physician in making recommendations for the care of an atrial fibrillation patient we propose specific tables and algorithms, with graded recommendations.CONCLUSIONS: On the evidence of data from the literature we propose simple algorithms and tables for the clinical management of atrial fibrillation in the individual patient. bleeding 10.26752/cuarzo.v21.n1.33 https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/33/32 https://doi.org/10.26752/cuarzo.v21.n1.33 53 39 2015-06-30T00:00:00Z 2015-06-30T00:00:00Z 0121-2133 2500-7181 2015-06-30 |
| institution |
FUNDACION UNIVERSITARIA JUAN N. CORPAS |
| thumbnail |
https://nuevo.metarevistas.org/FUNDACIONUNIVERSITARIAJUANN.CORPAS/logo.png |
| country_str |
Colombia |
| collection |
Revista Cuarzo |
| title |
Guía de práctica clínica para tratamiento de fibrilación auricular |
| spellingShingle |
Guía de práctica clínica para tratamiento de fibrilación auricular Forero Supelano, Victor Hugo brilación auricular embolísmo anticoagulación sangrado guía práctica clínica atención primaria anticoagulation embolism atrial fibrillation primary care guide clinical practice bleeding |
| title_short |
Guía de práctica clínica para tratamiento de fibrilación auricular |
| title_full |
Guía de práctica clínica para tratamiento de fibrilación auricular |
| title_fullStr |
Guía de práctica clínica para tratamiento de fibrilación auricular |
| title_full_unstemmed |
Guía de práctica clínica para tratamiento de fibrilación auricular |
| title_sort |
guía de práctica clínica para tratamiento de fibrilación auricular |
| title_eng |
Atrial fIbrillation - practical clinical guideline |
| description |
El tratamiento de la fibrilación auricular impone retos en cada caso. Nuestro propósito es brindar recomendaciones para el médico en atención primaria. Las fuentes de información principales en la elaboración de la guía fueron estudios primarios y agregativos.En general, el tratamiento de la fi brilación auricular requiere enfoque individualizado y es altamente recomendable aprovechar de manera pertinente las escalas clínicas disponibles para identificación de beneficios y riesgos según las alternativas terapéuticas.Para la toma de deciciones hay dos aspectos clave: 1) determinar justificación para profilaxis antitrombótica, 2) evaluar la estrategia más apropiada: control de frecuencia - control de ritmo. Las recomendaciones estan expuestas en tablas y algoritmos que requieren ser utilizadas según el contexto y características individuales en cada caso.
|
| description_eng |
Since the management of atrial fibrillation may be difficult in the individual patient, our purpose was to develop simple clinical recommendations to help the primary primary care physicians.SOURCES: Systematic review of the literature with evaluation of data-related evidence and framing of graded recommendations.SYNTHESIS: The management of atrial fibrillation requires individualised evaluation of the risks and benefits of therapeutic modalities, relying whenever possible on simple and validated tools. The two main points requiring a decision in clinical management are 1) whether or not to implement thromboembolic prevention therapy, and 2) whether preference should be given to a “rate control” or “rhythm control” strategy. To assist the physician in making recommendations for the care of an atrial fibrillation patient we propose specific tables and algorithms, with graded recommendations.CONCLUSIONS: On the evidence of data from the literature we propose simple algorithms and tables for the clinical management of atrial fibrillation in the individual patient.
|
| author |
Forero Supelano, Victor Hugo |
| author_facet |
Forero Supelano, Victor Hugo |
| topicspa_str_mv |
brilación auricular embolísmo anticoagulación sangrado guía práctica clínica atención primaria |
| topic |
brilación auricular embolísmo anticoagulación sangrado guía práctica clínica atención primaria anticoagulation embolism atrial fibrillation primary care guide clinical practice bleeding |
| topic_facet |
brilación auricular embolísmo anticoagulación sangrado guía práctica clínica atención primaria anticoagulation embolism atrial fibrillation primary care guide clinical practice bleeding |
| citationvolume |
21 |
| citationissue |
1 |
| publisher |
Fundación Universitaria Juan N. Corpas |
| ispartofjournal |
Revista Cuarzo |
| source |
https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/33 |
| language |
Español |
| format |
Article |
| rights |
http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Cuarzo - 2015 |
| references |
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther. 2012;10(12):1471-80. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fi brillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-6. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-94. Benezet-Mazuecos J, Rubio JM, Cortés M, et al. Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices. Europace. 2015;17(3):364-9. Yoneyama K, Harada T, Ito H, et al. Subclinical atrial fi brillation preceding cardioembolic stroke in a patient with systolic heart failure. Int J Cardiol. 2014;176(3):1036-8. Wachter R, Stahrenberg R, Gröschel K. Subclinical atrial fi brillation: how hard should we look? Heart. 2013;99(3):151-3. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-9. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fi brillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fi brillation in developed and developing nations. Glob Heart. 2014;9(1):113-9. Chan N, Paikin J, Hirsh J, Lauw M, Eikelboom J, Ginsberg J. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thrombosis and Haemostasis. 2014;111(5):798807. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152(3):420-6. Chiang C-EE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632-9. Stępińska J, Czerwińska K, Witkowski A, et al. Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI). Cardiol J. 2013;20(2):125-33. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart. 2013;99(2):127-32. Claridge SB, Kanaganayagam GS, Kotecha T. Atrial fi brillation guidelines. Don’t forget HASBLED score. BMJ. 2011;342:d3205. Cope S, Clemens A, Hammès F, Noack H, Jansen JP. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fi brillation stroke prevention trials. Value Health. 2015;18(2):234-49. Basili S, Raparelli V, Proietti M, Napoleone L, Ferroni P, Franconi F. Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women. Curr Vasc Pharmacol. 2015. Dentali F, Botto GL, Gianni M, Ambrosino P, Di Minno MN. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature. Int J Cardiol. 2015;185:72-77. Senoo K, Lip GY. Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fi brillation. Semin Thromb Hemost. 2015;41(2):146-53. Albertsen I, Rasmussen L, Overvad T, Graungaard T, Larsen T, Lip G. Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin A Systematic Review and Metaanalysis. Stroke. 2013;44(5):1329-1336. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100(2):247-52. Dzeshka M, Lane D, Lip G. Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk-Score Acronyms (CHADS2, CHA2DS2-VASc, R2CHADS2, HAS-BLED, ATRIA, and More). Clinical Cardiology. 2014;37(10):634-644. Lafuente-Lafuente C, Valembois L, Bergmann J-FF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fi brillation. Cochrane Database Syst Rev. 2015;3:CD005049. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, fl ecainide, and propafenone, for the management of atrial fi brillation. Europace. 2011;13(3):329-45. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365(10):883-91. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361(12):1139-51. Wallentin L, Lopes RD, Hanna M, et al. Effi cacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166-76. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fi brillation. Europace. 2013;15(5):625-651. Rolf S, Kornej J, Dagres N, Hindricks G. What can rhythm control therapy contribute to prognosis in atrial fi brillation? Heart. 2015. Weipert KF, Erkapic D, Schmitt J. [Rate and rhythm control in atrial fibrillation: Pharmacological approaches]. Herz. 2015;40(1):16-24. Smit MD, Crijns HJ, Tijssen JG, et al. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fi brillation data of the RACE II (RAte Control Effi cacy in permanent atrial fi brillation II) study. J Am Coll Cardiol. 2011;58(9):942-9. Hrynkiewicz-Szymanska A, Dluzniewski M, Platek AE, et al. Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. J Thromb Thrombolysis. 2014. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fi brillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Annals of internal medicine. 2011;155(10):660-7, W204. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate and rhythm-control therapies in patients with atrial fi brillation: a systematic review. Ann Intern Med. 2014;160(11):760-73. Abraham JM, Connolly SJ. Atrial fi brillation in heart failure: stroke risk stratification and anticoagulation. Heart Fail Rev. 2014;19(3):305-13. Steinberg B, Kim S, Thomas L, et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2014;129(20):20052012. Bekwelem W, Misialek JR, Konety S, et al. Echocardiographic measures of cardiac structure and function are associated with risk of atrial fi brillation in blacks: the Atherosclerosis Risk in Communities (ARIC) study. PLoS ONE. 014;9(10):e110111. Luong C, Thompson DJ, Bennett M, et al. Right atrial volume is superior to left atrial volume for prediction of atrial fibrillation recurrence after direct current cardioversion. Can J Cardiol. 2015;31(1):29-35. Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fi brillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377-87. Yoon YE, Oh I-YY, Kim S-AA, et al. Echocardiographic Predictors of Progression to Persistent or Permanent Atrial Fibrillation in Patients with Paroxysmal Atrial Fibrillation (E6P Study). J Am Soc Echocardiogr. 2015. Shi X-MM, Yuan H-TT, Guo H-YY, Guo J-PP, Shan Z-LL, Wang Y-TT. Electrophysiological characteristics of paroxysmal atrial fibrillation originating from superior vena cava: a clinical analysis of 30 cases. Int J Clin Exp Med. 2015;8(1):240-8. Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods for diagnosing atrial fi brillation using 12-lead ECG: A systematic review and meta-analysis. Int J Cardiol. 2015;184C:175-183. Penado S, Cano M, Acha O, Hernández J, Riancho J. Atrial fibrillation as a risk factor for stroke recurrence. The American Journal of Medicine. 2003;114(3):206210. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_dcae04bc |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2015-06-30 |
| date_accessioned |
2015-06-30T00:00:00Z |
| date_available |
2015-06-30T00:00:00Z |
| url |
https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/33 |
| url_doi |
https://doi.org/10.26752/cuarzo.v21.n1.33 |
| issn |
0121-2133 |
| eissn |
2500-7181 |
| doi |
10.26752/cuarzo.v21.n1.33 |
| citationstartpage |
39 |
| citationendpage |
53 |
| url2_str_mv |
https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/33/32 |
| _version_ |
1797159662850670592 |